Work

A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps2618

Authors: Andrea Elisabeth Wahner Hendrickson, Michael E. Menefee, Lynn C. Hartmann, Harry J. Long, Donald W. Northfelt, Joel M. Reid, Fleix Boakye-Agyeman, Karen S Flatten, Guy G Poirier, Janet Lensing, Charles Erlichman, Scott H. Kaufmann, Paul Haluska

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Comprehensive Cancer Center (Minnesota), Université Laval

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2808701886

Cites:

Cited by: 1

Related to: 10